Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niels D Prins

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Alzheimer'S Research & Therapy|November 13, 2013
Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the futureNiels D Prins, Philip Scheltens
Nature Reviews. Neurology|February 18, 2015
White matter hyperintensities, cognitive impairment and dementia: an updateNiels D Prins, Philip Scheltens
Nature Reviews. Neurology|December 7, 2010
Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal changeNiels D Prins, John C van Swieten
Alzheimer'S Research & Therapy|April 15, 2010
Can novel therapeutics halt the amyloid cascade?Niels D Prins, Pieter Jelle Visser, Philip Scheltens
Alzheimer'S Research & Therapy|September 23, 2011
Amyloid imaging in prodromal Alzheimer's diseaseRik Ossenkoppele, Bart Nm van Berckel, Niels D Prins
Alzheimer'S Research & Therapy|August 20, 2013
Amyloid imaging in clinical trialsRik Ossenkoppele, Niels D Prins, Bart Nm van Berckel
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial designDaniela Bertens, Betty M Tijms, Lisa Vermunt, et al.
Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.
The New England Journal of Medicine|March 28, 2003
Silent brain infarcts and the risk of dementia and cognitive declineSarah E Vermeer, Niels D Prins, Tom den Heijer, et al.
Stroke|July 19, 2008
Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan studyEwoud J van Dijk, Niels D Prins, Henri A Vrooman, et al.
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Alzheimer'S Research & Therapy|November 13, 2013
Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the futureNiels D Prins, Philip Scheltens
Nature Reviews. Neurology|February 18, 2015
White matter hyperintensities, cognitive impairment and dementia: an updateNiels D Prins, Philip Scheltens
Nature Reviews. Neurology|December 7, 2010
Alzheimer disease: MRI and CSF biomarkers in AD--accuracy and temporal changeNiels D Prins, John C van Swieten
Alzheimer'S Research & Therapy|April 15, 2010
Can novel therapeutics halt the amyloid cascade?Niels D Prins, Pieter Jelle Visser, Philip Scheltens
Alzheimer'S Research & Therapy|September 23, 2011
Amyloid imaging in prodromal Alzheimer's diseaseRik Ossenkoppele, Bart Nm van Berckel, Niels D Prins
Alzheimer'S Research & Therapy|August 20, 2013
Amyloid imaging in clinical trialsRik Ossenkoppele, Niels D Prins, Bart Nm van Berckel
Alzheimer'S & Dementia (New York, N. Y.)|November 11, 2017
The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial designDaniela Bertens, Betty M Tijms, Lisa Vermunt, et al.
Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.
The New England Journal of Medicine|March 28, 2003
Silent brain infarcts and the risk of dementia and cognitive declineSarah E Vermeer, Niels D Prins, Tom den Heijer, et al.
Stroke|July 19, 2008
Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan studyEwoud J van Dijk, Niels D Prins, Henri A Vrooman, et al.
Pageof 10